How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Business Services · Forecast 2027–2033
Biochip for COVID-19 Detection Market
- By Product Type: Microarray Biochips, Lab-on-a-Chip Devices, Electrochemical Biosensors, Optical Biosensors, Nanotechnology-based Biochips
- By Technology: PCR-based Biochips, Isothermal Amplification-based Biochips, Immunoassay-based Biochips, CRISPR-based Biochips, Microfluidics Technology
- By End User: Hospitals and Clinics, Diagnostic Laboratories, Point-of-Care Testing Centers, Research and Academic Institutes, Pharmaceutical and Biotechnology Companies
- By Sample Type: Nasopharyngeal Swabs, Saliva Samples, Blood Samples, Sputum Samples, Other Respiratory Samples
- By Detection Method: Nucleic Acid Amplification, Antigen Detection, Antibody Detection, Multiplex Detection
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Microarray Biochips leads By Product Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 16 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 305 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.184 →
- 12 Company Profiles 16 players: SWOT & benchmarking p.192 →
Full report · locked preview
Everything inside the Biochip for COVID-19 Detection Market report
A complete, evidence-based study - 12 chapters and 128 sections covering market size, segmentation across 5 axes, regional analysis and 16 company profiles, forecast to 2033.
Segmentation covered
Product Type 5
Technology 5
End User 5
Sample Type 5
Detection Method 4
Companies profiled
Abbott Laboratories
Thermo Fisher Scientific
Roche Diagnostics
Qiagen N.V.
Bio-Rad Laboratories
Cepheid (Danaher Corporation)
Becton
Dickinson and Company (BD)
Hologic Inc.
Siemens Healthineers
GenMark Diagnostics
Mesa Biotech (now part of Thermo Fisher Scientific)
+4 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
16 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Abbott Laboratories
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Thermo Fisher Scientific
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Roche Diagnostics
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Qiagen N.V.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Bio-Rad Laboratories
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Cepheid (Danaher Corporation)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Becton
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.191 →Dickinson and Company (BD)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Hologic Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Siemens Healthineers
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →GenMark Diagnostics
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Mesa Biotech (now part of Thermo Fisher Scientific)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →LumiraDx
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Mobidiag (now part of Hologic)
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Fujirebio
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Quidel Corporation
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.245 →
Global · 2025–2033
$3,006M by 2033 · 5.2% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Microarray Biochips51.0
- Lab-on-a-Chip Devices14.0
- Electrochemical Biosensors5.6
- Optical Biosensors15.0
- Nanotechnology-based Biochips14.3
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$659.3M → $880.0M · 3.7%
Europe$459.5M → $627.1M · 4.0%
Asia Pacific$419.5M → $666.3M · 6.0%
Latin America$259.7M → $367.0M · 4.4%
Middle East and Africa$199.8M → $333.3M · 6.6%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →5.192026
5.212027
5.212028
5.232029
5.242030
5.252031
5.272032
5.282033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Abbott Laboratories15.8
- Thermo Fisher Scientific19.5
- Roche Diagnostics9.5
- Qiagen N.V.9.0
- Bio-Rad Laboratories8.5
- Cepheid (Danaher Corporation)9.6
- Others28.1
Segment contribution to growth (%)
Fig. 18 · p.39 →Product Type12.8%
Technology13.4%
End User31.4%
Sample Type10.5%
Detection Method31.8%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America30.6
- Europe21.8
- Asia Pacific23.2
- Latin America12.8
- Middle East and Africa11.6
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Abbott Laboratories | 87 | 84 | 74 | 83 | 93 | 95 | 86 |
| Thermo Fisher Scientific | 76 | 92 | 75 | 89 | 83 | 69 | 81 |
| Roche Diagnostics | 77 | 88 | 86 | 79 | 75 | 86 | 82 |
| Qiagen N.V. | 79 | 69 | 72 | 72 | 64 | 76 | 72 |
| Bio-Rad Laboratories | 56 | 60 | 76 | 51 | 73 | 76 | 65 |
| Cepheid (Danaher Corporation) | 53 | 46 | 59 | 48 | 63 | 61 | 55 |
| Becton | 60 | 50 | 52 | 46 | 65 | 48 | 54 |
| Dickinson and Company (BD) | 51 | 36 | 40 | 46 | 53 | 47 | 46 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Abbott Laboratories
- Thermo Fisher Scientific
- Roche Diagnostics
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Abbott Laboratories | ✓ | ✓ | ◐ | ◐ | ✓ | ✓ |
| Thermo Fisher Scientific | ✓ | ✓ | ◐ | ✓ | ◐ | ✓ |
| Roche Diagnostics | ✓ | ✓ | ◐ | ◐ | ◐ | ✓ |
| Qiagen N.V. | ◐ | ◐ | ◐ | ◐ | ✓ | − |
| Bio-Rad Laboratories | ◐ | − | ✓ | − | ✓ | ◐ |
| Cepheid (Danaher Corporation) | − | − | ◐ | ◐ | ◐ | − |
| Becton | ◐ | − | − | − | − | − |
| Dickinson and Company (BD) | − | − | − | − | ◐ | ◐ |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Abbott Laboratories86
2Roche Diagnostics82
3Thermo Fisher Scientific81
4Qiagen N.V.72
5Bio-Rad Laboratories65
6Cepheid (Danaher Corporation)55
7Becton54
8Dickinson and Company (BD)46
Competitive tiers
§8.4 · p.172 →Leader3
Set the pace on share, breadth and innovation.
Abbott LaboratoriesThermo Fisher ScientificRoche Diagnostics
Challenger1
Strong scale, closing on the leaders.
Qiagen N.V.
Contender1
Focused players with pockets of strength.
Bio-Rad Laboratories
Niche3
Specialists in a single segment or region.
Cepheid (Danaher Corporation)BectonDickinson and Company (BD)
Go-to-market strategy
Land Product Type in North America, then scale across Biochip for COVID-19 Detection Market — a $37M beachhead inside a $695M market.
Beachhead (SOM)$37Mobtainable near-term
Serviceable (SAM)$261Mreachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale4 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion88 fit
Microarray Biochips
Best fit — highest urgency & budget in Product Type.
Economic buyer79 fit
Lab-on-a-Chip Devices
Strong fit — clear ROI and a fast path to value.
End user66 fit
Electrochemical Biosensors
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Product Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Technology & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + End User
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales47%
Partner / channel26%
Digital / self-serve19%
Marketplaces8%
Positioning & messaging
§GTM 2 · p.194 →For Product Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Biochip for COVID-19 Detection Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified46%
Sales qualified25%
Evaluation15%
Closed-won6%
$8.6KCAC
$36KLTV
4.2:1LTV : CAC
< 3 moCAC payback
Investment thesis
Biochip for COVID-19 Detection Market is a durable-growth opportunity — $6.51B by 2033, compounding at 9.2%.
TAM · 2025$3.22Btoday
TAM · 2033$6.51Bforecast
CAGR9.2%2027–2033
Cumulative$42.3Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$6.51BTotal addressable market
SAM$2.72BServiceable available market
SOM$561MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →9.2% CAGR
Demand compounds through 2033, outpacing GDP across Product Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Product Type moving from early to mainstream — durable secular demand.
Consolidation upside
16+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$6.51BLarge & growingTAM by 2033 at 9.2% CAGR
$2.72BServiceable nowreachable with today’s model
$561MBeachhead winobtainable near-term share
16+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$5.08BBear6.0% CAGR
$6.51BBase9.2% CAGR
$8.34BBull12.1% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Technology optionality
- Customer concentrationBroaden installed base beyond top accounts
Board pack · executive summary
Biochip for COVID-19 Detection Market — a $3.09B market by 2033. Plan: grow share from 6.8% to 11.2%.
Market size · 2033$3.09Btotal addressable
Market CAGR4.7%2027–2033
Target share11.2%from 6.8% today
Revenue ambition$346Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 6.8% | 11.2% | At risk |
| Revenue | $220M | $346M | On track |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | Ahead |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | At risk |
| Gross margin | 30.5% | 44.4% | Behind |
| Customer retention | 91.4% | 94.0% | Behind |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Product Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Technology capability
A defensible second engine — invest in Technology to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Product Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Technology
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $35M capacity & capability investment
- Greenlight bolt-on M&A in Technology
- Authorise North America expansion plan
- Fund R&D program for Product Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownAt risk
- Competitive share lossAt risk
- Input-cost & supply riskAhead
- Regulatory / policy changeAhead
- Execution & talentAhead
Sales deck · value proposition
Win the Biochip for COVID-19 Detection Market conversation — a $2.98B market you can size, segment and defend in minutes.
Market size · 2033$2.98Btotal opportunity
Growth5.3%CAGR to 2033
Addressable buyers1,777+accounts in scope
Typical ROI6.8×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Product Type
Goal Grow share in Product Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →6.8×return on cost, year one
< 3 mopayback period
$51K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
16+players profiled in this market
Coverage includes
Abbott LaboratoriesThermo Fisher ScientificRoche DiagnosticsQiagen N.V.Bio-Rad LaboratoriesCepheid (Danaher Corporation)BectonDickinson and Company (BD)+8 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Biochip for COVID-19 Detection Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Biochip for COVID-19 Detection Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Business Services · scroll →Biochip Scanner Market
Market size, share, segmentation and regional forecast.
$6.2B market · 2025 base year
View reportBiochips Spotter Market
Market size, share, segmentation and regional forecast.
$4.3B market · 2025 base year
View reportBiocidal Formulation Market
Market size, share, segmentation and regional forecast.
$4.2B market · 2025 base year
View reportBiocide Market
Market size, share, segmentation and regional forecast.
$6.0B market · 2025 base year
View reportBiocide Mildewcide Market
Market size, share, segmentation and regional forecast.
$4.4B market · 2025 base year
View reportBiocompatible 3D Printing Polymer Market
Market size, share, segmentation and regional forecast.
$4.5B market · 2025 base year
View reportBiocompatible Fiber Market
Market size, share, segmentation and regional forecast.
$6.2B market · 2025 base year
View reportBiocompatible Material Market
Market size, share, segmentation and regional forecast.
$6.1B market · 2025 base year
View reportBiocompatible Medical Adhesives Market
Market size, share, segmentation and regional forecast.
$4.2B market · 2025 base year
View reportBiocompatible Photosensitive Resin Market
Market size, share, segmentation and regional forecast.
$5.4B market · 2025 base year
View reportBiocomplex Deodorant Market
Market size, share, segmentation and regional forecast.
$1.4B market · 2025 base year
View reportBiocomposite Market
Market size, share, segmentation and regional forecast.
$3.7B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report ships as a formatted PDF, a fully editable XLSX containing all underlying data tables, and a presentation-ready PPT deck - so you can re-chart, re-model, or drop any figure straight into your own deck.